In Situ Programming of Armored CAR‐Macrophages by Microneedle‐Mediated Gene Delivery for Melanoma Immunotherapy

Despite clinical advances in CAR‐T therapy and immune checkpoint blockade, effective immunotherapy for solid tumors remains limited by restricted immune‐cell access and an immunosuppressive tumor microenvironment. Chimeric antigen receptor macrophages (CAR‐M) provide an alternative strategy by combining antigen‐directed myeloid programming with local immune remodeling. A self‐locking microneedle platform incorporating mannose‐modified nanoparticles (MNPs) enables localized in situ programming of CAR‐expressing macrophages at melanoma sites. The platform co‐delivers a tumor‐antigen‐directed CAR and a hypoxia‐responsive anti‐PD‐L1 single‐chain variable fragment (scPD‐L1). Initial studies in B16F10‐OVA tumors establish antigen‐dependent CAR activity and coordinated local immune remodeling. Therapeutic efficacy is subsequently evaluated in parental B16F10 tumors using an endogenous tyrosinase‐related protein 1 (TYRP1)‐directed CAR. MNP(TYRP1/scPD‐L1) microneedles delay tumor progression, prolong survival, and promote coordinated myeloid and CD8 + T‐cell responses, while providing lower terminal tumor burden, greater local surface CAR + tumor‐associated macrophage abundance, and reduced systemic exposure compared with dose‐matched intratumoral administration. Reciprocal depletion further shows that CAR‐programmed macrophages contribute to the antigen‐directed myeloid response, whereas CD8 + T cells are major downstream effectors required for maximal and sustained tumor control. These findings establish a localized transcutaneous strategy that coordinates antigen‐directed myeloid programming with adaptive antitumor immunity.

Authors

Institutions

Publication Details

Journal
Advanced Materials
Published
2026-11-18
DOI
https://doi.org/10.1002/adma.75787
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

In Situ Programming of Armored CAR‐Macrophages by Microneedle‐Mediated Gene Delivery for Melanoma Immunotherapy

Juhyeong Hong, Shayan Fakhraei Lahiji, Yong‐Hee Kim, Jaehyun Kim et al.
5 links
Advanced Materials
Cancer Immunotherapy and Biomarkers
article

In Situ Programming of Armored CAR‐Macrophages by Microneedle‐Mediated Gene Delivery for Melanoma Immunotherapy

Juhyeong Hong, Shayan Fakhraei Lahiji, Yong‐Hee Kim, Jaehyun Kim, Sangjin Kim, Kyungdong Kim, Hanseok Lim
article en

Abstract

Despite clinical advances in CAR‐T therapy and immune checkpoint blockade, effective immunotherapy for solid tumors remains limited by restricted immune‐cell access and an immunosuppressive tumor microenvironment. Chimeric antigen receptor macrophages (CAR‐M) provide an alternative strategy by combining antigen‐directed myeloid programming with local immune remodeling. A self‐locking microneedle platform incorporating mannose‐modified nanoparticles (MNPs) enables localized in situ programming of CAR‐expressing macrophages at melanoma sites. The platform co‐delivers a tumor‐antigen‐directed CAR and a hypoxia‐responsive anti‐PD‐L1 single‐chain variable fragment (scPD‐L1). Initial studies in B16F10‐OVA tumors establish antigen‐dependent CAR activity and coordinated local immune remodeling. Therapeutic efficacy is subsequently evaluated in parental B16F10 tumors using an endogenous tyrosinase‐related protein 1 (TYRP1)‐directed CAR. MNP(TYRP1/scPD‐L1) microneedles delay tumor progression, prolong survival, and promote coordinated myeloid and CD8 + T‐cell responses, while providing lower terminal tumor burden, greater local surface CAR + tumor‐associated macrophage abundance, and reduced systemic exposure compared with dose‐matched intratumoral administration. Reciprocal depletion further shows that CAR‐programmed macrophages contribute to the antigen‐directed myeloid response, whereas CD8 + T cells are major downstream effectors required for maximal and sustained tumor control. These findings establish a localized transcutaneous strategy that coordinates antigen‐directed myeloid programming with adaptive antitumor immunity.

Advanced Materials
Bioengineering Center (RU), Hanyang University (KR)
National Research Foundation of Korea, Korea Drug Development Fund, Ministry of Science and ICT, South Korea
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon